Background & Objective: There is no effective non-invasive monitoring method for transitional cell carcinoma of urinary tract(TCCU). It was recently reported that nuclear matrix protein 22(NMP22) could be used to diagnose TCCU. This study was designed to evaluate the significance of NMP22 in TCCU as a new urinary tumor marker and its influence factors.
Methods: The authors detected 87 patients with urinary system disease(including 29 cases with TCCU) with ELISA-NMP agent box. The patients with urinary infection were excluded.
Results: The positive value was set at more than 10 u/ml. The sensitivity and specificity of NMP22 on TCCU were 86.2% and 94.3%, respectively (benign diseases of urinary system used as control), with significant advantages over voided-urine cytology (86.2% vs 42.3%, P < 0.001). The main factors that caused false-positive results were urinary infection, the other malignant tumors of urinary system, bowel interposition, and nephrolith.
Conclusion: Urinary NMP22 is a good tumor marker and could be used an alternation of voided-urine cytology for monitoring and diagnosis of TCCU.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Detection of O25b-ST131 clone in extended spectrum beta-lactamase-producing E. coli from urinary tract infections in Mexico.
J Infect Dev Ctries
December 2024
Instituto Nacional de Salud Pública (INSP), Centro de Investigación Sobre Enfermedades Infecciosas (CISEI), Departamento de Diagnóstico Epidemiológico. Cuernavaca, Morelos, México.
Introduction: Escherichia coli has emerged as an important pathogen in urinary tract infections (UTIs) due to the rapid acquisition of antibiotic resistance genes. This enhances the ability of E. coli to colonize and creates therapeutic challenges within the healthcare system.
View Article and Find Full Text PDFA comparison on safety and efficacy between 24 Fr versus 18 Fr pneumatic balloon dilators for percutaneous treatment of renal stones between 10 and 20 mm: results from a contemporary cohort.
World J Urol
January 2025
Department of Urology, Azienda Socio Sanitaria Territoriale Lariana, Como, Italy.
Purpose: To assess differences in safety and efficacy between 24 and 18 Fr pneumatic balloon dilators for percutaneous nephrolithotripsy (PCNL) of renal stones between 10 and 20 mm.
Methods: Patients were randomized to dilatation with a 24 Fr (Group A) versus 18 Fr (Group B) Ultraxx pneumatic dilator (Cook Medical). In all procedures percutaneous puncture was performed under ultrasound guidance.
"Δ" Delta neobladder: a novel stentless simplified totally intracorporeal robotic technique.
Minerva Urol Nephrol
December 2024
Department of Urology, Campus Bio-Medico University Polyclinic Foundation, Rome, Italy.
Background: To report the first case series of RARC using a simplified technique for intracorporeal stentless neobladder formation.
Methods: From October 2022 to February 2023, 10 patients with high-risk bladder cancer underwent RARC at our Institution. RARC with extended pelvic lymph node dissection and totally intracorporeal neobladder using Hugo RAS system.
MYBL2 promotes proliferation of clear cell renal cell carcinoma by regulating TOP2A and activating AKT/mTOR signaling pathway.
FASEB J
January 2025
Department of Urology, Second Affiliated Hospital of Nanchang University, Nanchang, China.
Renal cell carcinoma (RCC) is one of the most common malignancies in the urinary system, and clear cell renal cell carcinoma (ccRCC) is the most common subtype. MYBL2 has been reported to be overexpressed in various tumors and associated with poor prognosis in patients, but its biological role in ccRCC remains unclear. In this study, we investigated the mRNA and protein expression levels of MYBL2 in ccRCC samples and evaluated the prognostic value of MYBL2 using TCGA dataset.
View Article and Find Full Text PDFHistopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract.
Cancer Med
January 2025
Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Introduction: Small cell neuroendocrine carcinoma of the urinary tract (SCNEC-URO) has an inferior prognosis compared to conventional urothelial carcinoma (UC). Here, we evaluate the predictors and patterns of relapse after surgery.
Materials And Methods: We identified a definitive-surgery cohort (n = 224) from an institutional database of patients with cT1-T4NxM0 SCNEC-URO treated in 1985-2021.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!